• Market Capitalisation market-capitalisation-info $3,920 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-338 Mln

Crispr Therapeutics AG (CRSP) Share Price

$70.66

As on 28-Nov-2023 16:05 EST

up-down-arrow $-0.95-1.33%

  • Prev Close info

    $71.61

  • Day's Openinfo

    $71.17

  • Today's Highinfo

    $71.74

  • Today's Lowinfo

    $69.44

  • Today's Volumeinfo

    1,852,962

  • 52 Week rangeinfo

    $37.55 - 76.19

Please wait...

Crispr Therapeutics AG (CRSP) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Crispr Therapeutics AG (CRSP)
73.83 82.40 39.92 28.50 -16.54 14.24 --
S&P BSE Sensex*
10.91 5.65 4.09 6.94 15.19 13.27 12.49
S&P Small-Cap 600#
-5.82 -5.34 -13.90 -6.30 5.30 2.98 5.53
As on 28-Nov-2023  |  *As on 01-Dec-2023  |  #As on 26-Oct-2023
2022
2021
2020
2019
2018
2017
Crispr Therapeutics AG (CRSP)
-46.36 -50.51 151.39 113.18 21.55 15.89
S&P Small-Cap 600
-17.42 25.27 9.57 20.86 -9.70 11.73
S&P BSE Sensex
4.44 21.99 15.75 14.38 5.87 27.91

Valuation

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Crispr Therapeutics AG (CRSP) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Crispr Therapeutics AG (CRSP)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Crispr Therapeutics AG (CRSP)

        CEO & Director

        Dr. Samarth Kulkarni Ph.D.

        Sr. VP, CFO & Principal Accounting Officer

        Mr. Brendan Smith M.B.A.

        Headquarters

        Zug

        FAQs for Crispr Therapeutics AG (CRSP)

        The total asset value of Crispr Therapeutics AG (CRSP) stood at $ 2,330 Mln as on 30-Jun-23

        The share price of Crispr Therapeutics AG (CRSP) is $70.66 (NASDAQ) as of 28-Nov-2023 16:05 EST. Crispr Therapeutics AG (CRSP) has given a return of -16.54% in the last 3 years.

        Crispr Therapeutics AG (CRSP) has a market capitalisation of $ 3,920 Mln as on 11-Aug-2023. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of Crispr Therapeutics AG (CRSP) is 2.01 times as on 11-Aug-2023, a -0.21% premium to its peers’ median range of 2.54 times.

        Since, TTM earnings of Crispr Therapeutics AG (CRSP) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Crispr Therapeutics AG (CRSP) and enter the required number of quantities and click on buy to purchase the shares of Crispr Therapeutics AG (CRSP).

        CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and VCTX211, an investigational, allogeneic, gene-edited, stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

        The CEO & director of Dr. Samarth Kulkarni Ph.D.. is Crispr Therapeutics AG (CRSP), and CFO & Sr. VP is Mr. Brendan Smith M.B.A..

        The promoters of Crispr Therapeutics AG (CRSP) have pledged 0% of the total equity as on Jun-23.

        Crispr Therapeutics AG (CRSP) Ratios
        Return on equity(%)
        -22.53
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0
        Dividend yield(%)
        0

        No, TTM profit after tax of Crispr Therapeutics AG (CRSP) was $-338 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $3,919.92 Mln
        • Revenue (TTM)revenue-information $170.10 Mln
        • Earnings (TTM) earning-information $-338.19 Mln
        • Cash date-information $1,768.10 Mln
        • Total Debt info $245.18 Mln
        • Insider's Holding 1.38%
        • Liquidity liquidity High
        • 52 Week range week-range $37.55 - 76.19
        • Shares outstanding share-outstanding 78,935,104
        • 9 Years Aggregate:

          CFO: $-305.47 Mln

          EBITDA: $-868.79 Mln

          Net Profit: $-843.69 Mln

        About The Company

        • IPO Date 19-Oct-2016
        • CEO & Director Dr. Samarth Kulkarni Ph.D.
        • Sr. VP, CFO & Principal Accounting Officer Mr. Brendan Smith M.B.A.
        • Listing key-listing NASDAQ: CRSP
        • Country Switzerland
        • Headquarters headquarters Zug
        • Website website https://www.crisprtx.com
        • Business

          CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9...  is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and VCTX211, an investigational, allogeneic, gene-edited, stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.  Read more

        Demystifying Stocks.

        At Value Research, we believe it's best to understand investments before diving in. And since 1990, we've been doing exactly that – helping & guiding lakhs of Indians with their investing journey. Join the journey.

        Sign Up for Free
        demystifying-mutual-fund

        What can Value Research do for you?

        solidify-your-fundamentals
        Solidify your fundamentals

        Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.

        track-all-your-investments
        Track all your investments

        Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.

        get-guidance-from-our-experts
        Get guidance from our experts

        Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.

        get-access-to-exclusive-analytics
        Get access to exclusive analytics

        Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.

        Explore it yourself, for free

        Sign up and get access to:

        Unlimited access to advice from India's top experts

        The most comprehensive analysis of funds and stocks in India

        A holistic portfolio manager to help track all your investments easily

        And much more, like guides, tools, webinars, videos and eBooks.

        share-fund-plan-icon